Thinking the big guns associated early news from a collaborator of ours whose novel PCR detection system for Invasive Circulating Tumor Cells we've adopted for showing our progress monitoring SM-88's eradication of those.
Press release from holding corporation of LineaRX
*******************
Master Services Agreement (MSA) with an existing customer of its Linea™ COVID-19 Assay Kit (the “Assay Kit”). The amendment doubles the undisclosed maximal value of the MSA to ensure the customer’s continuing access to the Assay Kit for the customer’s pooled COVID-19 surveillance testing program.
Concurrently, the Company announced the receipt of a purchase order for its Assay Kits and consumables to enable the customer to conduct 16,000 tests to be used for recurring surveillance testing and support the customer’s in-person graduation ceremonies in May 2021.
************""*
Massachusetts General (our collaborator with THYME 19 for COVID) is aligned to Boston University School of Health. Graduating scheduled for May 18th.
Applied DNA Secures Amendment to Master Services Agreement and Fourth Blanket Purchase Order from Linea™ COVID-19 Assay Kit Customer
Ensures Customer’s Continuing Access to Assay Kit for Pooled Surveillance Testing Program
Here's the only other service agreement I'm aware of that APDN has
November 26, 2019
Applied DNA Sciences Subsidiary LineaRx Signs Agreement with TYME Technologies for Functional Invasive Circulating Tumor Cell Assay Services in Pancreatic Cancer Trial
Demonstrates Growing Interest and Demand for Alternatives to Plasmids as Source of DNA in Pre-Clinical Therapeutic Applications
STONY BROOK, N.Y., – Applied DNA Sciences,
+_++++++++++++++++++++
A Guess, may be REAL GREAT HERE in 3 weeks
Gotta get to APDN Board. Mick, Hanuman see you there. Hanuman, I left SAVA way too soon. Hope you Killed IT:)
